Redx Pharma Future Growth

Future criteria checks 0/6

Redx Pharma's revenue and earnings are forecast to decline at 37.6% and 22.3% per annum respectively.

Key information

-22.3%

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth21.5%
Revenue growth rate-37.6%
Future return on equityn/a
Analyst coverage

Low

Last updated02 Apr 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:0RX - Analysts future estimates and past financials data (GBP Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/2025N/A-49N/A-481
9/30/202413-26N/A-241
9/30/20234-33-35-35N/A
6/30/20238-31-32-32N/A
3/31/202313-29-30-30N/A
12/31/202216-24-19-19N/A
9/30/202219-18-9-8N/A
6/30/202217-18-8-8N/A
3/31/202216-19-8-7N/A
12/31/202113-20-15-14N/A
9/30/202110-22-22-21N/A
6/30/20218-20-15-14N/A
3/31/20217-18-7-7N/A
12/31/20206-14-4-3N/A
9/30/20206-900N/A
6/30/20205-8-2-2N/A
3/31/20204-6-5-5N/A
12/31/20194-5-5-5N/A
9/30/20193-4-5-5N/A
6/30/20192-5-6-6N/A
3/31/2019N/A-7-8-8N/A
12/31/20180-8-13-13N/A
9/30/20180-9-17-17N/A
6/30/201815-1-4-4N/A
3/31/201831899N/A
12/31/20173151111N/A
9/30/20173021414N/A
6/30/201715-9N/A-1N/A
3/31/2017N/A-19N/A-16N/A
12/31/2016N/A-17N/A-14N/A
9/30/2016N/A-16N/A-13N/A
6/30/2016N/A-14N/A-11N/A
3/31/2016N/A-12N/A-9N/A
12/31/2015N/A-10N/A-8N/A
9/30/2015N/A-8N/A-7N/A
6/30/2015N/A-7N/A-6N/A
3/31/2015N/A-5N/A-5N/A
12/31/2014N/A-4N/A-4N/A
9/30/2014N/A-3N/A-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 0RX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 0RX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 0RX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 0RX's revenue is expected to decline over the next 3 years (-37.6% per year).

High Growth Revenue: 0RX's revenue is forecast to decline over the next 3 years (-37.6% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 0RX's Return on Equity is forecast to be high in 3 years time


Discover growth companies